BR112012031882A2 - dispersão sólida de tolvaptan e seu método de preparação - Google Patents

dispersão sólida de tolvaptan e seu método de preparação

Info

Publication number
BR112012031882A2
BR112012031882A2 BR112012031882A BR112012031882A BR112012031882A2 BR 112012031882 A2 BR112012031882 A2 BR 112012031882A2 BR 112012031882 A BR112012031882 A BR 112012031882A BR 112012031882 A BR112012031882 A BR 112012031882A BR 112012031882 A2 BR112012031882 A2 BR 112012031882A2
Authority
BR
Brazil
Prior art keywords
solid dispersion
tolvaptan
preparation
cross
polyvinylpyrrolidone
Prior art date
Application number
BR112012031882A
Other languages
English (en)
Inventor
Hao Chen
Shunjun Mao
Yuxia Wu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of BR112012031882A2 publication Critical patent/BR112012031882A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

dispersão sólida de tolvaptan e seu método de proparação. a presente invenção refere-se à descrição de uma dispersão sólida de tolvaptan e seu método de preparação. a dispersão sólida compreende tolvaptan e polivinilpirrolidona reticulada, em uma proporção em peso de 1:0,05-20, de preferência 1:0,1-10, mais preferivelmente 2:1. a dispersão sólida também pode compreender polímeros solúveis em água, tais como polivinilpirrolidona, hidroxipropilcelulose, hidroxietilcelulose ou metilcelulose. a proporção em peso de tolvapan: polivinilpirrolidona reticulada: polímeros solúveis em água é, de preferência, 2:1:0,1. a dispersão sólida exibe boa estabilidade termodinâmica e solubilidade. sua composição farmacêutica tem taxa de liberação melhorada e biodisponibilidade.
BR112012031882A 2010-06-25 2011-06-02 dispersão sólida de tolvaptan e seu método de preparação BR112012031882A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010102248840A CN102293734A (zh) 2010-06-25 2010-06-25 托伐普坦固体分散体及其制备方法
PCT/CN2011/075131 WO2011160541A1 (zh) 2010-06-25 2011-06-02 托伐普坦固体分散体及其制备方法

Publications (1)

Publication Number Publication Date
BR112012031882A2 true BR112012031882A2 (pt) 2016-11-08

Family

ID=45354575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012031882A BR112012031882A2 (pt) 2010-06-25 2011-06-02 dispersão sólida de tolvaptan e seu método de preparação

Country Status (12)

Country Link
US (1) US9408915B2 (pt)
EP (1) EP2586464B1 (pt)
JP (1) JP5991968B2 (pt)
KR (1) KR101815722B1 (pt)
CN (2) CN102293734A (pt)
AU (1) AU2011269506B2 (pt)
BR (1) BR112012031882A2 (pt)
CA (1) CA2801098C (pt)
HK (1) HK1166005A1 (pt)
MX (1) MX2012014251A (pt)
RU (1) RU2579745C2 (pt)
WO (1) WO2011160541A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793706B (zh) * 2012-08-14 2018-02-06 浙江华海药业股份有限公司 托伐普坦固体分散体的制备方法
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CN105530918A (zh) * 2013-09-25 2016-04-27 陶氏环球技术有限责任公司 包含有机液体稀释剂和特定羟烷基甲基纤维素的组合物
EP3268445A4 (en) * 2015-03-12 2018-07-25 Hercules LLC An oil and gas treatment composition comprising hydroxyethyl cellulose and crosslinked polyvinylpyrrolidone
JP2018024628A (ja) * 2016-08-02 2018-02-15 ニプロ株式会社 トルバプタンを含む非晶質固体分散体およびその製造方法
JP6838446B2 (ja) * 2017-03-22 2021-03-03 ニプロ株式会社 トルバプタン製剤およびその製造方法
WO2020122670A1 (ko) * 2018-12-14 2020-06-18 명인제약주식회사 톨밥탄을 포함하는 고체분산체 제조를 위한 약제학적 조성물 및 이의 제조방법
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
CN113171344B (zh) * 2021-04-12 2023-01-31 南京海纳医药科技股份有限公司 一种托伐普坦口服制剂及其制备方法
CN112972394B (zh) * 2021-04-16 2022-09-13 浙江工业大学 一种姜黄素固体分散体及其机械力制备方法
KR20230133029A (ko) 2022-03-10 2023-09-19 건양대학교산학협력단 톨밥탄을 포함하는 자가 유화 약물 전달 시스템 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2167649C2 (ru) * 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
JP2001335483A (ja) * 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
ITMI20022748A1 (it) * 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
JP5546715B2 (ja) * 2003-03-17 2014-07-09 日本たばこ産業株式会社 Ｃｅｔｐ阻害剤の医薬組成物
WO2005103693A2 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
GB0428152D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
TW201414469A (zh) * 2006-03-20 2014-04-16 Vertex Pharma 對包括ｖｘ-９５０之藥物實施噴霧乾燥之方法及由此方法製備之產物
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
JPWO2008081829A1 (ja) * 2006-12-27 2010-04-30 アステラス製薬株式会社 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
SI2180882T1 (sl) * 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Trdni matriksni farmacevtski pripravek

Also Published As

Publication number Publication date
CA2801098C (en) 2018-10-30
US20130102588A1 (en) 2013-04-25
JP2013530189A (ja) 2013-07-25
CA2801098A1 (en) 2011-12-29
AU2011269506B2 (en) 2015-04-09
EP2586464B1 (en) 2018-07-25
KR20130094281A (ko) 2013-08-23
CN102293734A (zh) 2011-12-28
CN102470178A (zh) 2012-05-23
HK1166005A1 (en) 2012-10-19
KR101815722B1 (ko) 2018-01-30
MX2012014251A (es) 2013-01-18
JP5991968B2 (ja) 2016-09-14
AU2011269506A1 (en) 2013-01-10
WO2011160541A1 (zh) 2011-12-29
CN102470178B (zh) 2013-06-05
EP2586464A1 (en) 2013-05-01
RU2012157685A (ru) 2014-07-27
EP2586464A4 (en) 2014-11-26
US9408915B2 (en) 2016-08-09
RU2579745C2 (ru) 2016-04-10

Similar Documents

Publication Publication Date Title
BR112012031882A2 (pt) dispersão sólida de tolvaptan e seu método de preparação
EP3626253A3 (en) Stable formulations of linaclotide
EA201600366A1 (ru) Производные бензимидазол-пролина
MD20160012A2 (ro) Formulare de inhibitori SYK
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
WO2014152389A8 (en) Imaging agent for detection of diseased cells
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
JO3475B1 (ar) ناهضات مستقبل سوماتوستاتين نوع فرعي 4 (sstr4) جديدة
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
CY1114260T1 (el) 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγο, μεθοδοι για την παραγωγη αυτου και χρηση αυτου για την αγωγη παθησεων
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
BR112013003216A2 (pt) composições sintéticas de ácido biliar e métodos
AR067361A1 (es) 4- cloro-4- alcoxi-1,1,1- trifluoro -2- butanonas, su preparacion y su uso para preparar 4- alcoxi-1,1,1- trifluoro-3 -buten-2- onas
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
IN2013MU02206A (pt)
IN2015DN03921A (pt)
PH12015502632A1 (en) Cxcr7 receptor modulators
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
IN2011KN05169A (pt)
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
MX2011012859A (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.